TransMedics Group, Inc. (TMDX)
| Market Cap | 5.04B |
| Revenue (ttm) | 605.49M |
| Net Income (ttm) | 190.29M |
| Shares Out | 34.30M |
| EPS (ttm) | 4.87 |
| PE Ratio | 30.16 |
| Forward PE | 58.83 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,132,908 |
| Open | 139.50 |
| Previous Close | 145.26 |
| Day's Range | 137.34 - 147.80 |
| 52-Week Range | 62.07 - 156.00 |
| Beta | 1.98 |
| Analysts | Buy |
| Price Target | 152.33 (+3.63%) |
| Earnings Date | Feb 24, 2026 |
About TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung tra... [Read more]
Financial Performance
In 2025, TransMedics Group's revenue was $605.49 million, an increase of 37.13% compared to the previous year's $441.54 million. Earnings were $190.29 million, an increase of 436.58%.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price target is $152.33, which is an increase of 3.63% from the latest price.
News
TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results
ANDOVER, Mass., Feb. 27, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics Group, Inc. (TMDX) Q4 2025 Earnings Call Transcript
TransMedics Group, Inc. (TMDX) Q4 2025 Earnings Call Transcript
TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results
ANDOVER, Mass., Feb. 24, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Feb. 20, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics to Present at Upcoming March Investor Conferences
ANDOVER, Mass., Feb. 17, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
ANDOVER, Mass., Feb. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE Trial
ANDOVER, Mass., Feb. 9, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...
TransMedics: Italian NOP Program Reinforces Huge International Opportunity
TransMedics: Italian NOP Program Reinforces Huge International Opportunity
TransMedics: Strong Growth And A Better Setup
I see a clear path for TransMedics to deliver at least mid-20% revenue growth in 2026, with upside as year-over-year comparisons get easier. I believe operating margins will continue to expand as scal...
TransMedics Group, Inc. (TMDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
TransMedics Group, Inc. (TMDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
TransMedics Announces New Global Headquarters and Expansion at Assembly Innovation Park in Somerville, Massachusetts
ANDOVER, Mass., Jan. 12, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a global leader in organ transplant technologies and services, today announced the signing of a lo...
TransMedics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
ANDOVER, Mass., Dec. 30, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics Group: I Estimate A Large Upside By The End Of 2028
TransMedics is reaffirmed as a buy, with significant upside potential based on improved margins and slower share dilution. I estimate 2028 revenue at $1.35 billion, driven by achieving 10k transplants...
TransMedics to Participate in the Piper Sandler 37th Annual Healthcare Conference
ANDOVER, Mass. , Nov. 18, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks
Short interest data offers a look into investor sentiment and potential risk within the stock market and can help investors gauge how much skepticism or confidence the market has in a company's future...
Polen U.S. Small Cap Growth Q3 2025 Portfolio Performance And Attribution
During the third quarter of 2025, the U.S. Small Cap Growth Composite Portfolio returned 21.4% gross and 21.1% net of fees. Bloom Energy is a provider of solid oxide fuel cells that play a critical ro...
TransMedics: Growth Tailwinds Should Provide Upside In 2026
TransMedics delivered solid year-over-year growth in Q3, despite seasonal weakness and concerns over U.S. liver market saturation. The next-gen heart and lung trials, along with an increased focus on ...
TransMedics: Q3 Results Disappointed, As Expected (Rating Upgrade)
TransMedics shares dropped after Q3 results beat consensus but missed high investor expectations, creating a favorable entry point. Q3 is seasonally weak for TMDX, but the current selloff makes valuat...
TransMedics Group, Inc. (TMDX) Q3 2025 Earnings Call Transcript
TransMedics Group, Inc. ( TMDX) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Waleed Hassanein - Founder, President, CEO & Director Gerardo Hernandez - CFO & Treasurer Confe...
TransMedics Reports Third Quarter 2025 Financial Results
ANDOVER, Mass. , Oct. 29, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
TransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025
ANDOVER, Mass. , Oct. 15, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...